Abstract |
Bone marrow failure is the major cause of early mortality in patients with dyskeratosis congenita (DC); early trials with conventional conditioning regimens were associated with remarkable chronic morbidity and mortality, and the optimal conditioning regimen for these patients remains undetermined. We report a case of a child afflicted with DC who underwent related full HLA-matched stem cell transplant (SCT) using a regimen of low dose cyclophosphamide and antithymocyte globulin (ATG). The regimen was well tolerated and associated with no significant short-term toxicity.
|
Authors | M Ayas, A Al-Musa, A Al-Jefri, A Al-Seraihi, M Al-Mahr, S Rifai, H El-Solh |
Journal | Pediatric blood & cancer
(Pediatr Blood Cancer)
Vol. 49
Issue 1
Pg. 103-4
(Jul 2007)
ISSN: 1545-5009 [Print] United States |
PMID | 16317729
(Publication Type: Case Reports, Journal Article)
|
Chemical References |
- Antilymphocyte Serum
- HLA Antigens
- Immunosuppressive Agents
- Cyclophosphamide
|
Topics |
- Antilymphocyte Serum
(administration & dosage)
- Child, Preschool
- Cyclophosphamide
(administration & dosage)
- Dyskeratosis Congenita
(therapy)
- Graft vs Host Disease
(immunology, prevention & control)
- HLA Antigens
(immunology)
- Histocompatibility Testing
- Humans
- Immunosuppressive Agents
(therapeutic use)
- Male
- Stem Cell Transplantation
(methods)
- Transplantation Conditioning
- Transplantation, Homologous
|